Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation...
IPO
Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...
Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO
Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic...
Protein Drug Developer B&K Co., Ltd from Qingdao Eyes Hong Kong IPO
B&K Co., Ltd, known as Bio-Bank Corp., a biopharmaceutical company specializing in protein drug development...
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the...
Bio-Bank Corp. Aims for HKEX IPO with Focus on PDGF Drug Development
B&K Corporation Limited, known as Bio-Bank Corp., has recently filed an initial public offering (IPO)...
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed...
LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s...
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an...
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...
Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price
China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...
Weigao Blood Purification Aims for USD 190 Million in Shanghai Stock Exchange IPO
Shandong Weigao Blood Purification Products Co., Ltd, a dominant player in China’s blood purification sector,...
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public...
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...
Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services
Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...
Sandoz Becomes Independent After Spin-Off from Novartis
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...